Lupin launches eye drug in the US

Pharma company Lupin said it launched Moxifloxacin Hydrochloride eye solution in the US.

Lupin’s Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base), is an AT1 rated generic equivalent of Novartis Pharms Corp.’s Vigamox Ophthalmic solution.

It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the organisms.

Vigamox Ophthalmic solution had US sales of USD 267.9 million.

Moxifloxacin belongs is an antibiotic that belongs to the fluoroquinolone family of drugs.

These are extremely potent and wipeout bacteria that belong to a wide range of families. As such, these drugs have sometimes been blamed for disbiosis, or the killing of friendly bacteria that reside in the human gut. Disbiosis, in turn, is often blamed for irritable bowel syndrome.

The drugs are used in a wide range of applications, including for urinary infections, ear, eye and other areas.

Lupin focuses on cardiovascular, diabetology, asthma, pediatric, CNS, anti-infective and NSAID space and holds global leadership position in the Anti-TB segment.

It is the 4th and the 6th largest generics pharmaceutical company by market capitalization and revenues globally.